Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C15H16N2O2.2ClH.H2O |
| Molecular Weight | 603.537 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.Cl.OC(=O)C1=CC2=C(CC(CN3C=CN=C3)CC2)C=C1.OC(=O)C4=CC5=C(CC(CN6C=CN=C6)CC5)C=C4
InChI
InChIKey=HPUSTZZITOBRFQ-UHFFFAOYSA-N
InChI=1S/2C15H16N2O2.2ClH.H2O/c2*18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17;;;/h2*3-6,8,10-11H,1-2,7,9H2,(H,18,19);2*1H;1H2
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H16N2O2 |
| Molecular Weight | 256.2997 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A possible involvement of thromboxane A2 and peptide leukotrienes in hyperresponsiveness of Sephadex-treated rat lung parenchyma. | 1999-01 |
|
| Inhibitory effect of thromboxane A2 synthetase inhibitor, DP-1904, on antigen-induced contraction of human lung parenchyma. | 1996-12 |
|
| The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in man after repeated oral doses. | 1990-07 |
Patents
Sample Use Guides
Japanese normal male volunteers received repeated oral doses of 200 mg every 12 h for 4 doses, or 400 mg every 24 h for 2 doses, or 200 mg every 12 h for 14 doses.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: An augmented contraction and elevated thromboxane (TX) B2 release were observed, when the isolated parenchyma from Sephadex-treated rats was stimulated by 5-hydroxytryptamine (5-HT).
In the Sephadex-induced hyperresponsiveness model, Nafagrel at the concentrations of 3 x 10(-7) to approximately 3 x 10(-6) M, reduced the augmented contraction.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:18 GMT 2025
by
admin
on
Mon Mar 31 17:59:18 GMT 2025
|
| Record UNII |
7CH5E50P0D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50924328
Created by
admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
|
PRIMARY | |||
|
183604
Created by
admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
|
PRIMARY | |||
|
7CH5E50P0D
Created by
admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
|
PRIMARY | |||
|
122956-67-6
Created by
admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |